SCHEMBL7866809

SCHEMBL7866809

CCC(C)CCCC(N)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.52
NOS1 P29475 6/20 0.49
DDAH1 O94760 3/20 0.49
NOS2 P35228 5/20 0.47
NOS3 P29474 4/20 0.47
CYP2C19 P33261 2/20 0.47
BHMT Q93088 1/20 0.47
BHMT2 Q9H2M3 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ARG2 P78540 4/20 0.47
ARG1 P05089 3/20 0.47
CYP1A2 P05177 3/20 0.46
TSHR P16473 2/20 0.46
CYP3A4 P08684 1/20 0.46
GLA P06280 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
SLC1A3 P43003 2/20 0.45
SLC1A2 P43004 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10073274 1.00 GSR (0.52) GSRNOS1DDAH1NOS2NOS3
SCHEMBL24514466 0.94 GSR (0.55) GSRNOS1DDAH1NOS2NOS3
SCHEMBL5034721 0.87 BHMT (0.60) GSRBHMTBHMT2KMT2ACYP1A2
SCHEMBL1199780 0.87 BHMT (0.60) GSRBHMTBHMT2KMT2ACYP1A2
Hydrochloric Acid SCHEMBL7712717 0.85 BHMT (0.58) GSRBHMTBHMT2KMT2AARG2
Hydrochloric Acid SCHEMBL1198729 0.85 BHMT (0.58) GSRBHMTBHMT2KMT2AARG2
SCHEMBL16431861 0.82 ACE2 (0.59) GSRNOS1DDAH1NOS2NOS3
D-Glutamate SCHEMBL27832572 0.82 SLC1A2 (0.60) GSRNOS1DDAH1BHMTKMT2A
SCHEMBL29289 0.82 GSR (0.71) GSRNOS1NOS2NOS3CYP2C19
SCHEMBL29291 0.82 GSR (0.71) GSRNOS1NOS2NOS3CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927155-B2 Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta George Mason Research Foundation, Inc. (US) 2021-02-23 US disclosed
US-20190352351-A1 DUAL INHIBITORY ACTION PEPTIDOMIMETIC INHIBITOR FOR IL-33 AND IL-1BETA George Mason Research Foundation, Inc. 2019-11-21 US disclosed
WO-2012051663-A1 ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2012-04-26 WO disclosed
WO-2010130007-A1 ANTIMICROBIAL COMPOUNDS MONASH UNIVERSITY (AU) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927155-B2 Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta IL33, IL1R1, IL1RN GSR 3937/4885NOS1 980/4885DDAH1 3407/4885
US-20190352351-A1 DUAL INHIBITORY ACTION PEPTIDOMIMETIC INHIBITOR FOR IL-33 AND IL-1BETA IL33, IL1R1, IL1RN GSR 3937/4885NOS1 980/4885DDAH1 3407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.